- Home
- KPTI vs SQNS Comparison
KPTI vs SQNS Comparison
Compare KPTI & SQNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- SQNS
- Stock Information
- Founded
- KPTI 2008
- SQNS 2003
- Country
- KPTI United States
- SQNS France
- Employees
- KPTI N/A
- SQNS N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- SQNS Semiconductors
- Sector
- KPTI Health Care
- SQNS Technology
- Exchange
- KPTI Nasdaq
- SQNS Nasdaq
- Market Cap
- KPTI 44.5M
- SQNS 46.5M
- IPO Year
- KPTI 2013
- SQNS 2011
- Fundamental
- Price
- KPTI $4.21
- SQNS $4.52
- Analyst Decision
- KPTI Strong Buy
- SQNS Strong Buy
- Analyst Count
- KPTI 7
- SQNS 1
- Target Price
- KPTI $45.43
- SQNS $7.50
- AVG Volume (30 Days)
- KPTI 95.1K
- SQNS 9.6M
- Earning Date
- KPTI 08-05-2025
- SQNS 08-22-2025
- Dividend Yield
- KPTI N/A
- SQNS N/A
- EPS Growth
- KPTI N/A
- SQNS N/A
- EPS
- KPTI N/A
- SQNS 2.16
- Revenue
- KPTI $142,126,000.00
- SQNS $38,858,000.00
- Revenue This Year
- KPTI $2.09
- SQNS N/A
- Revenue Next Year
- KPTI $12.90
- SQNS $93.87
- P/E Ratio
- KPTI N/A
- SQNS $1.81
- Revenue Growth
- KPTI 1.19
- SQNS 40.06
- 52 Week Low
- KPTI $3.51
- SQNS $0.95
- 52 Week High
- KPTI $16.95
- SQNS $5.50
- Technical
- Relative Strength Index (RSI)
- KPTI 41.48
- SQNS 87.95
- Support Level
- KPTI $4.23
- SQNS $1.34
- Resistance Level
- KPTI $5.14
- SQNS $2.68
- Average True Range (ATR)
- KPTI 0.38
- SQNS 0.52
- MACD
- KPTI 0.04
- SQNS 0.29
- Stochastic Oscillator
- KPTI 24.45
- SQNS 76.77
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About SQNS Sequans Communications S.A.
Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its offer 5G/4G chips and modules fully optimized for non-smartphone devices. The company covers applications such as smart mobility and logistics, smart utility meters, smart cities, smart industries, e-health and wellness, and smart homes to name few. The Company has one operating segment, which is the design and marketing of semiconductor components for cellular wireless systems. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.